DASMAN DIABETES INSTITUTE
🇰🇼Kuwait
- Country
- 🇰🇼Kuwait
- Ownership
- -
- Established
- 2006-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
30
Active:1
Completed:7
Trial Phases
3 Phases
Phase 1:1
Phase 4:3
Not Applicable:20
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Not Applicable
20 (83.3%)Phase 4
3 (12.5%)Phase 1
1 (4.2%)Tirzepatide Use in People With Obesity and Type 1 Diabetes
Not Applicable
Not yet recruiting
- Conditions
- Type1diabetesObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Dasman Diabetes Institute
- Target Recruit Count
- 60
- Registration Number
- NCT07096908
- Locations
- 🇰🇼
Dasman Diabetes Institute, Kuwait, Sharq, Kuwait
Compare Multiple Daily Injections With Carbohydrate Counting or With Simplified Qualitative Meal-Size Estimation in Type 1 Diabetes
Not Applicable
- Conditions
- Type 1 Diabetes (T1D)
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Dasman Diabetes Institute
- Target Recruit Count
- 34
- Registration Number
- NCT07037810
- Locations
- 🇰🇼
Dasman Diabetes Institute, Kuwait City, Kuwait
Structured Education Program and Glycemic Control in Adolescents With Type 1 Diabetes
Not Applicable
Recruiting
- Conditions
- Type 1 Diabetes (T1D)Type 1 Diabetes Mellitus (T1DM)
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Dasman Diabetes Institute
- Target Recruit Count
- 128
- Registration Number
- NCT06984133
- Locations
- 🇰🇼
Dasman Diabetes Institute, Kuwait City, Sharq, Kuwait
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Phase 4
Not yet recruiting
- Conditions
- Type 1 Diabetes (T1D)
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Dasman Diabetes Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06922656
- Locations
- 🇰🇼
Dasman Diabetes Institute, Kuwait City, Kuwait
🇶🇦Hamad Medical Corporation, Qatar, Doha, Qatar
🇸🇦Diabetes and Endocrine Treatment Center, Prince Sultan Military Medical City. Kidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Alfaisal Univeristy, Riyadh, Kingdom of Saudi Arabia, Riyadh, Saudi Arabia
LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy
Not Applicable
Not yet recruiting
- Conditions
- Obesity
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Dasman Diabetes Institute
- Target Recruit Count
- 232
- Registration Number
- NCT06885736
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found